The reduction leaves DAFNA holding 476,826 shares, still representing $15.61 million at the period’s close. The fund’s continued investment, despite the trimming, suggests not outright disapproval, but a recalibration. One must ask: what prompts such a move after a period of considerable appreciation? The answer, predictably, is not a simple one.
Note the indirect nature of the acquisition. The shares are held via The Wesley and Katherine Mitchell Living Trust – a perfectly respectable arrangement, of course, but one that adds a layer of delightful opacity. It’s always more interesting when things aren’t entirely straightforward. The price, a mere $42.48 per share, suggests either remarkable foresight or a certain…optimism.
The pronouncements surrounding AI are legion, the capital expenditure astronomical. One anticipates, therefore, a corresponding ascent in valuation. Instead, a muted performance, a quiet retreat. This discrepancy, observed by many, has prompted speculation of a bubble’s deflation. However, I propose a different interpretation, one informed by the apocryphal writings of the cartographer, Señor Valerius. He posited that true value is not found in the readily apparent, but in the distortions, the anomalies that betray a deeper, hidden order.
The filing reveals a subtle shift in DAFNA’s holdings. The stake, once a more prominent bloom within the portfolio, now represents 1.36% of the fund’s $430.52 million in reportable assets, a gentle decline from the previous quarter’s 1.90%. It is as if the fund, observing the stock’s ascent, has simply rebalanced its bouquet, ensuring no single flower overshadows the others.
They increased their holdings in Biohaven during the last quarter of 2025. Another $8.92 million. The total stake? $10.78 million. Up from before. More shares. A slightly bigger number on a spreadsheet. The stock, of course, has other ideas. It’s down, dramatically, and that’s the thing, isn’t it? We chase numbers while the world does what it will.
The figures, presented thusly, offer a cold precision, yet conceal the warmth of human ambition and the chill of market uncertainty. The value assigned, derived from the weighted average purchase price of $58.98, and the closing price of $52.88 on the eighteenth of March, are but fleeting measurements, susceptible to the whims of fortune and the anxieties of investors.
The filing with the Securities and Exchange Commission reveals a new stake, a deliberate entry into a company that has, of late, failed to impress. Apellis currently represents 1.93% of RTW Investment’s reportable assets as of December 31, 2025 – a not insignificant sum, but hardly a commitment that would signal a complete shift in strategy.
According to those number-crunching geniuses at S&P Global Market Intelligence, the stock price went up more than 10%. Ten percent! That’s enough to buy, oh, a slightly used bookmark. But still, progress!
According to an SEC filing dated February 17, 2026, RTW Investments, LP augmented its Cogent Biosciences holdings by 4,124,755 shares during the reporting period. The estimated value of this transaction, calculated using the mean unadjusted closing price for the quarter, totaled $115.95 million. The quarter-end position in Cogent Biosciences experienced a combined increase of $219.88 million, reflecting both trading activity and market appreciation.
The thing is, everyone keeps saying “know what might happen.” As if knowing makes it any less terrifying. It’s like knowing you’re about to stub your toe doesn’t make the actual stubbing any less painful. Still, let’s try to be rational. Let’s dissect this. There’s good news, apparently. And also, less-good news. Naturally.